¡¾ÌáÒªÐÎò¡¿Ñо¿Åúעʯɼ¼î¼×ÔÚ¼õÇáÌÇÄò²¡ÓÕµ¼µÄÉöËðÉË¡¢Ö¬ÖÊ´úлÔÓÂÒºÍÑ×Ö¢·½ÃæÏÔʾ³öÓÐÏ£ÍûµÄÖÎÁƹ¦Ð§¡£
¡¾ÌáÒªÐÎò¡¿Ñо¿Åúעʯɼ¼î¼×ÔÚ¼õÇáÌÇÄò²¡ÓÕµ¼µÄÉöËðÉË¡¢Ö¬ÖÊ´úлÔÓÂÒºÍÑ×Ö¢·½ÃæÏÔʾ³öÓÐÏ£ÍûµÄÖÎÁƹ¦Ð§¡£
½üÆÚ£¬ÓÉÕã½´óѧҽѧԺÁ¥Êô¶ùͯҽԺÉöÄÚ¿ÆÍŶÓÓë97¹ú¼ÊºÏ×÷¿ªÕ¹µÄʯɼ¼î¼×ÖÎÁÆÌÇÄò²¡Éö²¡µÄ¶à×éѧÆÊÎöÑо¿½ÒÏþÁË×îÐÂÑо¿Ð§¹û£¬Ñо¿Åú×¢Îúʯɼ¼î¼×ÔÚ¼õÇáÌÇÄò²¡ÓÕµ¼µÄÉöËðÉË¡¢Ö¬ÖÊ´úлÔÓÂÒºÍÑ×Ö¢·½ÃæÏÔʾ³öÓÐÏ£ÍûµÄÖÎÁƹ¦Ð§¡£¸ÃÑо¿ÒѽÒÏþÓÚ¡¶Pharmacological Research¡·ÔÓÖ¾£¬È«ÃûΪ“Huperzine A targets Apolipoprotein E: A potential therapeutic drug for diabetic nephropathy based on omics analysis”¡£
ÔçÔÚ2020Ä꣬Õã½´óѧҽѧԺÁ¥Êô¶ùͯҽԺ¾ÍÓë97¹ú¼ÊºÏ×÷¿ªÕ¹¹ýÑÎËáä强ÐÂÆ¬¶Ô¶ùͯÐÂÐ͹Ú×´²¡¶¾Ñ¬È¾µÄÁÆÐ§¼°Çå¾²ÐÔÆÀ¼ÛÑо¿¡£ÏÖÔÚÔÙ´ÎÁªÊÖ£¬ÓÖÔÚÐµļ²²¡ÁìÓòÈ¡µÃÁËϲÈ˵ÄЧ¹û¡£
ʯɼ¼î¼×£º×ÔÈ»À¡ÔùµÄ¶àÃæÄÜÊÖ
ʯɼ¼î¼×(Huperzine A£¬Hup A)×÷ΪÑÇÖÞÖ²ÎïÉß×ãʯɼµÄÌáÈ¡ÎïÁÙ´²Ö÷ÒªÓÃÓÚÉñ¾ÍËÐÐÐÔ²¡ÖÎÁÆ£¬µ«½üÄêÀ´Ñо¿·¢Ã÷ÆäÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖоßÓÐÏÔÖøµÄ½µÑªÌǺͿ¹Ñ××÷Óᣵ«Æä¸üÆÕ±éµÄ±£»¤×÷Óã¬ÌØÊâÊǶÔÌÇÄò²¡ÁíÒ»²¢·¢Ö¢ÌÇÄò²¡Éö²¡Éö¹¦Ð§µÄ±£»¤×÷ÓÃÈÔδ±»Ñо¿¡£
ÌÇÄò²¡Éö²¡£ºÇÄȻDZÔڵĿµ½¡É±ÊÖ
ÌÇÄò²¡£¨DM£©×÷Ϊ³£¼û²¡¡¢¶à·¢²¡£¬ÊÇÑÏÖØÍþвÈËÀ࿵½¡µÄÌìÏÂÐÔ¹«¹²ÎÀÉúÎÊÌâ¡£ÏÖÔÚÔÚÌìϹæÄ£ÄÚ£¬ÌÇÄò²¡»¼²¡Âʺͻ¼²¡ÈËÊý¼±¾çÉÏÉý£¬¾Ý¹ú¼ÊÌÇÄò²¡Í¬ÃË£¨IDF£©Í³¼Æ£º2021ÄêÈ«Çò³ÉÄêÌÇÄò²¡ÈËÊýÒÑ´ï5.37ÒÚ£¬½Ï2019ÄêÔöÌí½ü16%£¬Ô¤¼Æµ½2045ÄêÈ«ÇòÌÇÄò²¡»¼²¡×ÜÈËÊý½«µÖ´ï7.83ÒÚ£»2021ÄêÈ«ÇòÒòÌÇÄò²¡éæÃüÈËÊý´ï670Íò¡£
½ü40¶àÄêÀ´£¬Ëæ×ÅÎÒ¹ú¾¼Ã¸ßËÙÉú³¤¡¢ÉúÑÄ·½·¨Î÷·½»¯¡¢¶¼»á»¯ºÍÉú³ÝÀÏÁ仯¡¢·ÊÅÖÂÊÉÏÉý£¬ÎÒ¹úÌÇÄò²¡»¼²¡ÂÊÒ²³Ê¿ìËÙÔöÌíÇ÷ÊÆ£º1980ÄêÎÒ¹ú³ÉÈËÌÇÄò²¡»¼²¡ÂÊΪ0.67%£¬2007 Äê´ï9.7%£¬2017Äê¸ü¸ß´ï 11.7%¡£ÌÇÄò²¡Ç°ÆÚµÄ±ÈÀý¸ü¸ß¡£¸üΪÑÏÖØµÄÊÇÎÒ¹úÔ¼ÓÐ50%µÄÌÇÄò²¡Î´±»Õï¶Ï£»°ÕÁ˽ÓÊÜÖÎÁÆÕߣ¬ÌÇÄò²¡¿ØÖÆ×´Ì¬Ò²²»²ÇÏë¡£IDFÊý¾ÝÏÔʾ£¬×èÖ¹2021ÄêÎÒ¹ú³ÉÈËÌÇÄò²¡ÊýĿΪ1.41ÒÚ¡£ÎÒ¹úÒÑÈ»³ÉΪȫÌìÏÂÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò¡£
¶øÌÇÄò²¡Éö²¡(diabetic nephropathy£¬DN)ÊÇÌÇÄò²¡×îÖ÷ÒªÇÒ×îÑÏÖØµÄ²¢·¢Ö¢Ö®Ò»£¬·¢²¡»úÖÆÖØ´ó£¬Éæ¼°Ñõ»¯Ó¦¼¤¡¢Ñ×Ö¢¡¢ÏËά»¯ºÍϸ°ûµòÍö£¬ÁÙ´²ÌØÕ÷ΪһÁ¬ÐÔ°×ÂѰ×ÄòÉøÍ¸ÔöÌí£¬ÉöСÇòÂ˹ýÂÊ£¨eGFR£©¾ÙÐÐÐÔϽµ£¬×îÖÕÉú³¤ÎªÖÕÄ©ÆÚÉö²¡£¨ESRD£©£¬½ìʱÉöÔ๦Ч»ù±¾Ëðʧ£¬ÑݱäΪÉöË¥½ß£¬ÌåÄÚ·ºÆð´ó×Ú¶¾ËØ»ýÖü£¬Ë®¡¢µç½âÖÊ¡¢Ëá¼îʧºâ£¬ÖÂËÀÂʸߣ¬Ê®·ÖΣÏÕ¡£
¹ØÓÚÌÇÄò²¡Éö²¡£¬ÏÖÔÚµÄÁÙ´²ÖÎÁÆÈÔÒÔÔçÆÚ¿ØÖÆÑªÌÇ¡¢ÑªÑ¹ÎªÖ÷£¬¾ÙÐÐÖÁÍíÆÚÔòÐèÒª½ÓÄÉ͸ÎöµÈÉöÔàÌæ»»ÁÆ·¨¾ÙÐÐÖÎÁÆ¡£ÉÐÎÞÓÐÓõÄÒ©Îï¸ÉÔ¤ÊֶΡ£
¶à×éѧÆÊÎö£ºÕ¹ÏÖʯɼ¼î¼×µÄ×÷ÓûúÖÆ
±¾´ÎÑо¿ÖУ¬Ñо¿Ö°Ô±½ÓÄÉÁËת¼×é¡¢´úл×顢΢ÉúÎï×éºÍÍøÂçÒ©ÀíѧµÈ¶à×é±ð¶àѧ¿Æ×ÛºÏÆÊÎöÒªÁ죬̽ÌÖÁËʯɼ¼î¼×¹ØÓÚÌÇÄò²¡Éö²¡µÄÖÎÁÆ×÷Óá£Ñо¿Ð§¹ûÏÔʾ£¬Ê¯É¼¼î¼×Äܹ»Í¨¹ýµ÷¿ØApoEµÄ±í´ï£¬Æðµ½±£»¤ÉöÔà¡¢µ÷Àí´úл¡¢¸ÄÉÆ³¦µÀ΢ÉúÎïȺ¡¢¸ÄÉÆÑ×Ö¢µÈ×÷Ó᣸ÃÑо¿Ê×´ÎÌṩÁËʯɼ¼î¼×¶ÔDNÖÎÁÆ×÷ÓõÄÖ¤¾Ý£¬Åúעʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿ØApoE£¬³ÉΪһÖÖDZÔÚµÄÔ¤·ÀºÍÖÎÁÆDNµÄÒ©Îï¡£ÏêϸÈçÏ£º
1. ÉöÔà±£»¤×÷ÓãºÔÚÁÙ´²ÖУ¬ÄòÂѰ×ÊÇÆÀ¹ÀÉö¹¦Ð§ºÍËðÉË¡¢ÌáÐÑÉöÔ༲²¡µÄÖ÷ÒªÖ¸±ê¡£Ñо¿Åú×¢£¬ÔÚÐÛÐÔSD´óÊó¸øÒ©Ê¯É¼¼î¼×ºó£¬Óë±ÈÕÕµÄδʹÓÃʯɼ¼î¼×µÄDN´óÊóÏà±È£¬Ê¹ÓÃÁËʯɼ¼î¼×µÄDN´óÊóÄòÂѰף¨uALB£©Ë®Æ½·ºÆð½µµÍ£¬²¢ÇÒÆäÉöÔàÖ¸Êý£¨kidney index£©¡¢Ñª¼¡ôû£¨SCr£©¡¢ÄòËØµª£¨BUN£©Ë®Æ½½ÔÓиÄÉÆ¡££¨ÈçÏÂͼ£©
£¨×¢£ºNCΪÕý³£´óÊó£»DNΪ»¼DN´óÊó£»DN+Hup AΪʹÓÃÊÇʯɼ¼î¼×µÄDN´óÊó¡££©


ÁíÍ⣬´óÊóÉöСÇò£¨Glomerulus£©ºÍÉöС¹Ü£¨Renal tubule£©µÄ½á¹¹ËðÉËÔÚʯɼ¼î¼×ÖÎÁÆÏÂÒ²ÓÐËù¼õÇᣬά³ÖÕý³£ÉöСÇòÂ˹ý¹¦Ð§Ëù±ØÐèµÄÉö²¡ÂѰף¨Nephrin£©ºÍ×ãÍ»ÂѰף¨Podocin£©µÄÂѰ×ÖÊˮƽÔÚʯɼ¼î¼×¸øÒ©ºóÒ²ÏÔÖø»ØÉý¡£
±ÈÕÕδÓÃÒ©µÄDN´óÊó£¬Ê¹ÓÃʯɼ¼î¼×ºóµÄ´óÊóÉöÔ๦Чָ±êÒÔ¼°½á¹¹ËðÉËÔÚʹÓÃʯɼ¼î¼×ºó»ù±¾¶¼ÓÐËù¸ÄÉÆ¡£Òò´Ë¿ÉÒԵóö£¬Ê¯É¼¼î¼×±£´æ×ŶÔÉöÔàµÄ±£»¤×÷Óá£
2. »ùÒò±í´ïÓ°Ï죺ΪÁË̽Ë÷ʯɼ¼î¼×ÖÎÁÆDNµÄ·Ö×Ó»úÖÆ£¬Ñо¿¶ÔÉöÔà×éÖ¯¾ÙÐÐÁËת¼×é²âÐòºÍ²î±ð±í´ï»ùÒò(DEG)ÆÊÎö¡£Ð§¹ûÏÔʾ£¬ÔÚDN×éÖÐÏÔÖøÉϵ÷µÄApoEºÍApoC 2ÔÚʯɼ¼î¼×ÖÎÁƺóÏÔÖø½µµÍ¡£
3. ´úлÎïµ÷Àí£ºÑо¿Í¨¹ýÖ÷ÒòËØÆÊÎö£¨PCA£©ºÍÆ«×îС¶þ³ËÅбðÆÊÎö£¨PLS-DA£©À´Ñо¿ÉöÔà´úлת±ä·¢Ã÷£¬NC×éºÍDN×éµÄÑùÆ·¾ßÓÐÏÔ×ÅÊèÉ¢ÐÔ£¬¶øDN+Hup AµÄÂþÑܸü¿¿½üNC×é¡£ÕâÒ²¾ÍÒâζ×Å£¬Ê¹ÓÃÁËʯɼ¼î¼×µÄDN´óÊóµÄÉöÔà´úлÏà±ÈÓÚδÓÃÒ©µÄDN´óÊ󣬯äÉöÔà´úлԽ·¢¿¿½üÓÚÕý³£´óÊó¡£ÕâÅúעʯɼ¼î¼×ÖÎÁÆÒ»¶¨Ë®Æ½Éϻָ´ÁËDN´óÊóµÄ´úл¡££¨ÈçÏÂͼ£©

4. ³¦µÀ΢ÉúÎïȺ¸ÄÉÆ£ºShannonÖ¸ÊýÊÇÆÀ¹À΢ÉúÎïȺÂä¶àÑùÐÔ»ò¸»ºñ¶ÈµÄ³£ÓÃÖ¸±ê£¬ÊýÖµÔ½¸ßÅúעȺÂäµÄ¶àÑùÐÔÔ½¸ß£¬¹ÊÑо¿ÓÃÆäÀ´ÆÀ¹Àʯɼ¼î¼×¶Ô´óÊ󳦵À΢ÉúÎïȺµÄÓ°Ï졣Ч¹ûÏÔʾ£¬DN×éµÄShannon¶àÑùÐÔÖ¸Êý½µµÍ£¬¶øDN+Hup A×éµÄShannon¶àÑùÐÔÖ¸ÊýÔöÌí£¬Åúעʯɼ¼î¼×´¦Öóͷ£µ÷ÀíÁË´óÊ󳦵À΢ÉúÎïȺ¶àÑùÐÔ¡££¨ÈçÏÂͼ£©

ÁÙ´²ÒâÒ壺ApoE×÷ΪÉúÎï±ê¼ÇÎï
Ϊ̽ÌÖApoEÓëDNÏà¹ØÉúÎï±ê¼ÇÎïµÄÁÙ´²Ïà¹ØÐÔ£¬Ñо¿ÄÉÈëÁË428ÀýDN»¼Õß¾ÙÐнøÒ»²½ÆÊÎö¡£
ÌÇ»¯ÑªºìÂѰף¨HbA1c£©ÊÇѪÌÇ¿ØÖÆË®Æ½µÄÖ÷ÒªÖ¸±ê£¬Í¨³£ÒÔΪ£¬ÌÇ»¯ÑªºìÂѰ×Ũ¶È¿ÉÓÐÓõط´Ó¦ÒÑÍù8~12ÖÜÆ½¾ùѪÌÇˮƽ¡£Ñо¿·¢Ã÷£¬HbA1cÓëApoE³ÊÕýÏà¹Ø£¬ÌáÐÑApoEµÄ±í´ïËæHbA1cˮƽµÄÉý¸ß¶øÔöÌí¡£
ÔÚÉö¹¦Ð§·½Ã棬ÔÚ¸ßÂѰ×ÄòˮƽÏ£¬ApoE±í´ïÓë24 hÄòÂѰ×ˮƽ³ÊÇ¿ÕýÏà¹Ø£¬Åú×¢Ëæ×ÅÂѰ×ÄòˮƽµÄÉý¸ß£¬ApoE±í´ïÒ²Éý¸ß¡£
ÁíÍ⣬Ñо¿»¹·¢Ã÷£¬ApoEÓëѪÇå°×ÂѰף¨ALB£©¡¢Ö¬ÖÊÉúÎï±ê¼ÇÎï¡¢Ñ×Ö¢±ê¼ÇÎÓÈÆäÊÇCRPºÍHsCRP£©µÈ¶¼±£´æ½ÏΪÏÔÖøµÄÏà¹ØÐÔ¡££¨ÈçÏÂͼ£©

Ñо¿»¹¾ÙÐÐÁËApoEÇõÍÑéÖ¤£¬Çõͺóµ¼ÖÂÑ×Ö¢¼õÇᡢϸ°ûÕ³¸½ÔöÌíºÍϸ°û»îÐÔÉý¸ß¡£ÓëNC×éÏà±È£¬ÇõÍ×éÖÐ×ÔÊÉÌå±ê¼ÇÎïLC 3B II/LC 3B IÂѰױí´ïÏÔÖø½µµÍ£¬Åú×¢ÆÏÌÑÌÇÓÕµ¼¸ü¸ßµÄ×ÔÊÉˮƽ£¬ÇõÍApoE½µµÍ×ÔÊÉˮƽ¡£
ÍøÂçÒ©Àíѧ£ºÑé֤ʯɼ¼î¼×µÄ¶à°Ðµã×÷ÓÃ
ͨ¹ýÍøÂçÒ©ÀíѧÆÊÎö£¬Ñо¿Ö°Ô±½øÒ»²½ÑéÖ¤ÁËʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿Ø¶à¸öÓëDNÏà¹ØµÄ»ùÒòºÍ´úл;¾¶À´Ê©Õ¹×÷ÓÃ, ²¢ÇÒÄܹ»Í¨¹ý¿ØÖÆÏ¸°ûµòÍö¶øÆð±£»¤×÷Óá£
½áÂÛ£ºÊ¯É¼¼î¼×µÄDZÁ¦ÓëδÀ´Ñо¿Æ«Ïò
¸ÃÑо¿Ê×´ÎÌṩÁËʯɼ¼î¼×¶ÔDNÖÎÁÆ×÷ÓõÄÖ¤¾Ý£¬Åúעʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿ØApoE£¬³ÉΪһÖÖDZÔÚµÄÔ¤·ÀºÍÖÎÁÆDNµÄÒ©Îï¡£Ö»¹ÜÑо¿È¡µÃÁËÁîÈ˹ÄÎèµÄЧ¹û£¬µ«ÈÔÐè½øÒ»²½µÄÁÙ´²ÊÔÑéºÍ´ó¹æÄ£¶à×éѧÊý¾ÝÑéÖ¤À´ÆÀ¹Àʯɼ¼î¼×µÄÁÙ´²ÖÎÁÆÇ±ÄÜ¡£
ÌÇÄò²¡Éö²¡µÄÖÎÁÆÊÇÒ»¸öÖØ´óµÄÀú³Ì£¬µ«ÕâÏîÑо¿ÎªÎÒÃÇÌṩÁËеÄÊӽǺÍÏ£Íû¡£Ëæ×ÅÑо¿µÄÉîÈ룬ÎÒÃÇÆÚ´ýʯɼ¼î¼×Äܹ»³ÉΪÌÇÄò²¡»¼ÕßµÄи£Òô¡£ÈÃÎÒÃÇÒ»Æð¹Ø×¢ÕâÒ»ÁìÓòµÄ×îÐÂÏ£Íû£¬ÎªÌÇÄò²¡»¼Õß´øÀ´¸ü¶àµÄÏ£ÍûºÍÑ¡Ôñ¡£
Ñо¿ÎÄÏ×ȪԴ£º

ÉùÃ÷£º
1.±¾ÐÂÎÅÖ¼ÔÚ·ÖÏíѧÊõÇ°ÑØ¶¯Ì¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿»ùÓÚѧÊõÄ¿µÄ²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£
2.97¹ú¼ÊÖÆÒ©²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍÆ¼ö¡£
ɨ¶þάÂëÓÃÊÖ»ú¿´
Ïà¹ØÍÆ¼ö